These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1420 related items for PubMed ID: 15865225

  • 1. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group.
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA, Valera-Bestard B, Arizcorreta-Yarza A, González-Serrano M, Torre-Cisneros J, Santos I, Vergara S, Gutiérrez-Valencia A, Girón-González JA, Macías J, López-Cortés LF, Pineda JA.
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [Abstract] [Full Text] [Related]

  • 8. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Mariño A, González M, Núñez M, Soriano V.
    J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F, SMIEC II Investigators.
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [Abstract] [Full Text] [Related]

  • 10. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.
    J Acquir Immune Defic Syndr; 2007 Feb 01; 44(2):174-8. PubMed ID: 17106276
    [Abstract] [Full Text] [Related]

  • 11. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group.
    J Infect Dis; 2012 Sep 15; 206(6):961-8. PubMed ID: 22807523
    [Abstract] [Full Text] [Related]

  • 12. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 13. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
    Larrey D, Carenco C, Guyader D, Boyer N, Benhamou Y, Pageaux GP, Rouzier R, Marcellin P.
    Antivir Ther; 2012 Jan 02; 17(5):927-32. PubMed ID: 22611092
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R, Cariti G, Nasta P, Capetti A, Ravasio V, Galli M, Raise E, Palmieri G, Iannacone C, Puoti M.
    Liver Int; 2015 Jan 02; 35(1):120-9. PubMed ID: 25041136
    [Abstract] [Full Text] [Related]

  • 17. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.
    J Gastroenterol Hepatol; 2007 Jun 02; 22(6):832-6. PubMed ID: 17565637
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study.
    Milazzo L, Caramma I, Mazzali C, Cesari M, Olivetti M, Galli M, Antinori S.
    J Antimicrob Chemother; 2010 Apr 02; 65(4):735-40. PubMed ID: 20118492
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.